

## **Ophthalmologica**

Ophthalmologica 2014;231:180-184 DOI: 10.1159/000359987

Published online: February 18, 2014

## **EVICR.net – European Vision Institute Clinical** Research Network, EEIG

The European Vision Institute Clinical Research Network -EVICR.net – is a network of European ophthalmological clinical research sites, dedicated to perform clinical research in ophthalmology with the highest standards of quality, following the European and International Directives for Clinical Research according to harmonized standard operating procedures (SOPs) in order to strengthen the capacity of the European Union to explore the determinants of ophthalmic diseases and to develop and optimize the use of diagnostic, prevention and treatment strategies in ophthalmology.

It is a platform for clinical research in ophthalmology in Europe and a useful industry resource in the process of development of new drugs and medical devices. At present, EVICR.net has 80 Member Centres from 17 European countries.

EVICR.net Coordinating Centre is located at AIBILI in Coimbra, Portugal.

## Aims and Objectives

The main aims and objectives of EVICR.net are:

- To guarantee a high level of quality and excellence in ophthalmology clinical research performed by its members according to International Conference on Harmonization-Good Clinical Practices (ICH-GCP) Guidelines
- To promote multinational clinical research within the European Union
- To coordinate training activities for its members
- To serve as a resource for industry in performing clinical research in ophthalmology
- To promote quality, transparency and optimal use of clinical research data
- To communicate with patients and citizens about the challenges and opportunities raised by clinical research in ophthalmology.

## Organization

The General Assembly consists of all EVICR.net members and is the supreme organ of the Network.

The Steering Committee is responsible for the activities of the EVICR.net and acts as its decision-making body within the framework set by the General Assembly. The Steering Committee consists of up to seven representatives: the Chairman, the Coordinator of each Expert Committee and the CEO of the Coordinating Centre.

The Expert Committees have a fundamental role in the scientific organization of the EVICR.net and cover the following main areas of research: Age-Related Macular Degeneration (AMD) and Retinal Dystrophies; Diabetic Retinopathy and Retinal Vascular Diseases; Glaucoma; Anterior Segment, and Reading Centers.

There are also two Transversal Sections that work together with the Expert Committees, when applicable: Medical Devices and Rare Diseases.

The Industry Advisory Board advises the Steering Committee in all matters of strategic relevance, particularly pertaining collaborations with industry. The Industry Advisory Board is composed of individuals or representatives of companies who have given support to the activities of EVICR.net and at the moment is composed by Alcon, Allergan, Bayer, Novartis, Pfizer, Santen and Théa.

The Coordinating Centre, AIBILI, is the contact point for the members and industry when performing ophthalmological clinical research in Europe. Annually the Coordinating Centre updates the EVICR.net Research Resources Directory where all members have their resources listed: staff, equipment and facilities as well as their scientific areas of clinical research and the five most relevant publications. All members have access to a restricted area in the website that is also kept updated by the Coordinating Centre. The Coordinating Centre is responsible for the certification of EVICR. net Clinical Site Members.

**KARGER** 

**Table 1.** Number of members per country

Austria	2	
Belgium	3	
Denmark	2	
France	8	
Germany	15	
Greece	2	
Ireland	1	
Israel	1	
Italy	10	
Poland	1	
Portugal	7	
Slovakia	1	
Slovenia	1	
Spain	9	
Switzerland	3	
The Netherlands	4	
United Kingdom	10	
Total	80	



Fig. 1. Number of members per country.

### 8th Annual Members Meeting

The 8th EVICR.net Annual Members Meeting took place in Paris, France, on October 14–15, 2013. The meeting was attended by 100 participants from Member Centres, CROs and Industry Advisory Board Members (table 1, fig. 1).

Elections for the Expert Committees took place in the Scientific Sections that resulted in the new composition of Expert Committees. A new Scientific Section designated as Anterior Segment has emerged from the fusion of the Cornea, Cataract and Refractive Surgery and Ocular Surface and Inflammation Expert Committees. Two Transversal Sections were created, Medical Devices and Rare Diseases, that will address evaluation of investigator-driven clinical trials (IDCTs) in association with the Expert Committees.

**Table 2.** Multinational clinical research studies (2010–2013)

Year	IDCTs			Industry	Total
	no funding	EU funding	industry grant	registries	
2010	2	_	_	_	2
2011	2	1	_	_	3
2012	2	2	1	2	7
2013	2	3	3	3	11

Presentations from industry representatives sharing projects and experiences in an open way also took place. The EVICR.net annual meeting will take place in Coimbra, Portugal, on November 17–18.

## **Clinical Trials and Registries**

The EVICR.net Coordinating Centre assumes the leadership of coordination and management of IDCTs in ophthalmology across Europe through the Network. EVICR.net Members have the opportunity to participate in IDCTs within the Network as well as to submit abstracts for IDCTs to the Coordinating Centre in order to be evaluated by a specific Expert Committee. If approved they will have access to support in coordinating and implementing the IDCT (table 2, fig. 2).

EVICR.net IDCTs have been growing in the last years, giving the opportunity for investigators to perform multinational clinical research of high quality (compliant with ICH-GCP Guidelines) assuming that the rights, safety and well-being of the trial subjects are protected and that the clinical data are credible. EVICR.net has contributed to the improvement of diagnostic, prevention and treatment strategies in ophthalmology. EVICR.net has at the moment 11 ongoing multinational clinical research studies of which 3 are European Union-funded (table 3).

AMD and Retinal Dystrophies Clinical Trials

*Eur-USH:* European Young Investigators Network for Usher Syndrome. EU-funded project. ClinicalTrials.gov No. NCT01954953.

Registries

*LHON*: A registry on Leber's Hereditary Optic Neuropathy. Sponsor: Santhera. ClinicalTrials.gov No. NCT01892943.


Diabetic Retinopathy and Retinal Vascular Diseases Clinical Trials

*ECR-RET-2010-02:* Identifying progression of retinal disease in eyes with NPDR in diabetes type 2 using noninvasive procedures. ClinicalTrials.gov No. NCT01145599.

EUROCONDOR: Neurodegeneration as an early event in the pathogenesis of diabetic retinopathy: a multicenter, prospective, phase II/III, double-blind randomized controlled trial to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest diabetic retinopathy. EU-funded project. EudraCT No. 2012-001200-38. ClinicalTrials.gov No. NCT01726075.

**Table 3.** Multinational clinical research studies per ophthalmology subspecialty

Ongoing clinical research	Area of subspecialty					
	AMD and retinal dystrophies	diabetic retinopathy and retinal vascular diseases	glaucoma	anterior segment		
Clinical trials (IDCTs)  Registries (industry)	Eur-USHª LHON	RET-2010-02 EUROCONDOR <sup>a</sup> Proteus <sup>b</sup> Artes <sup>b</sup> Polaris	STRONG <sup>a</sup> SPORT <sup>b</sup>	CCR-2010-01		
		IRISS				
Total $(n = 11)$	2	6	2	1		



**Fig. 2.** Number of multinational clinical research studies.

*PROTEUS*: Prospective, randomized, multicenter, open label, phase II/III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP in monotherapy in the treatment of patients with high risk proliferative diabetic retinopathy. IDCT grant from Novartis. EudraCT No. 2013-003640-23.

*ARTES*: A collaborative retrospective trial on the efficacy and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema. IDCT grant from Allergan.

#### Registries

*POLARIS:* A noninterventional study in patients with diabetic macular edema with central involvement to assess the effectiveness of existing anti-vascular endothelial growth factor treatment regimens. Sponsor: Bayer. ClinicalTrials.gov No. NCT01771081.

IRISS: An open-label registry study of the safety of Iluvien® (fluocinolone acetonide 190  $\mu g$  intravitreal implant in applicator). Sponsor: Alimera. ClinicalTrials.gov No. NCT01998412.

Glaucoma

Clinical Trials

*STRONG:* European consortium for the Study of a Topical Treatment of Neovascular Glaucoma. EU-funded project. EudraCT 2014-000239-18.

*SPORT*: A randomized, 3 months', crossover, single-masked, investigator-led, multicenter trial on open-angle glaucoma or ocular hypertension patients. IDCT grant from Allergan. EudraCT 2013-003490-10.

Anterior Segment

Clinical Trial

*ECR-CCRS-2010-01:* European project for the determination of average biometric values of human eyes. ClinicalTrials.gov No. NCT01173614.

### **Standard Operating Procedures**

EVICR.net has developed a quality system for its members compliant with ICH-GCP Guidelines. It provides for free to its members 9 Organizational SOPs. All our Clinical Site Members agree to adopt these SOPs in their centers, which will be checked before they are certified as Sites of Excellence.

The implementation of these 9 Organizational SOPs will permit the Clinical Sites to have a standard way of working and in compliance with ICH-GCP Guidelines when performing clinical trials.

EVICR.net has also developed 31 Technical SOPs for performing specific ophthalmic examinations or evaluations that can be used within the Network for clinical trials. These SOPs are also made available to our members.

In parallel, EVICR.net has developed 22 Organizational SOPs for the Reading Centres so they can work as a network of Reading Centers and be able to have the capacity to respond to the industry needs for grading ophthalmological images in a standardized way with the most novel equipment.

At the moment we have 53 Clinical Sites certified of which 43 are re-certified (more than 2 years' certificate).

## Collaboration with European Clinical Research Infrastructure Network (ECRIN)

EVICR.net is participating in the ECRIN Integrating Activities project, specifically in the WorkPackage dedicated to medical devices. ECRIN has become a European Research Infrastructure Consortium (ERIC) and has now its statutes published in the official journal of the EU (December 2013). The EVICR.net has started discussing its integration as an Affiliate Partner of ECRIN-ERIC an Organ-Specific Clinical Research Network, providing its expertise in clinical research in ophthalmology.

## **Alliances and Partnerships**

EVICR.net has established preferred alliances with two CROs, AppleTree (Switzerland) and Eurotrials (Portugal), for the EVICR. net Clinical Site certification process, to perform an independent evaluation visit of the Clinical Sites. Collaborations are being established with other CROs to move forward multinational clinical research in ophthalmology.

## Next Meetings - 2014

- Industry Advisory Board during ARVO, Orlando, USA: May 5
- Diabetic Retinopathy and Retinal Vascular Diseases Expert Committee
  - during EURETINA, London, UK: September 11–14
- Glaucoma
  - during European Glaucoma Society, Nice, France: June 7-11
- Anterior Segment Expert Committee during ESCRS, London, UK: September 13–17
- 9th EVICR.net Members Meeting Coimbra, Portugal: November 17–18

# EVICR.net – European Network of Clinical Research in Ophthalmology

Chairman

Jose Sahel, MD, PhD

Steering Committee

Jose Saĥel, MD, PhD – AMD and Retinal Dystrophies Expert Committee Coordinator

José Cunha-Vaz, MD, PhD – Diabetic Retinopathy and Retinal Vascular Diseases Expert Committee Coordinator

Ingeborg Stalmans, MD, PhD – Glaucoma Expert Committee Coordinator

Jorge Alió, MD, PhD – Anterior Segment Expert Committee Coordinator

Tunde Peto, MD, PhD, FHCO, FHCD – Reading Centres Expert Committee Coordinator

Marie-José Tassignon, MD, PhD – Medical Devices Transversal Section Coordinator

Birgit Lorenz, MD, PhD – Rare Diseases Transversal Section Coordinator

Cecília Martinho, BSc - CEO, Coordinating Centre (AIBILI)

Contacts

EVICR.net

AIBILI, Azinhaga de Santa Comba, Celas

PT-3000-548 Coimbra (Portugal)

Tel. +351 239 480 101/15

Fax +351 239 480 117

E-mail evicrnet@aibili.pt

Website www.evicr.net

## **List of EVICR.net Members (per Country)**

#### Austria

- CS No. 19: Medical University of Vienna, Department of Ophthalmology, Vienna
- CS No. 83: Hommer Ophthalmology Institute, Vienna

#### Belgium

- CS No. 8: Ghent University Hospital, Department of Ophthalmology, Ghent
- CS No. 12: Antwerp University Hospital, Department of Ophthalmology,
- CS No. 18: University Hospital Leuven, Department of Ophthalmology,

#### Denmark

- CS No. 30: Glostrup Hospital, Department of Ophthalmology, Copenhagen University, Glostrup
- CS No. 73: Odense University Hospital, Department of Ophthalmology,

## France

- CS No. 3: Centre Hospitalier Creteil, University Eye Clinic, Paris
- CS No. 6: Centre National d'Ophthalmologie des Quinze-Vingts, Centre d'Investigation Clinique, Paris
- CS No. 13: CHU Gabriel Montpied, Unité de Recherche Clinique, Service d'Ophtalmologie, Clermont-Ferrand
- CS No. 14: Hôpital Lariboisière, Department of Ophthalmology, Paris
- CS No. 42: University Hospital, CHU Dijon, Department of Ophthalmology,
- CS No. 48: CLAIROP: Centre loco-régional d'Amiens pour l'Innovation et la Recherché en Ophtalmologie Pédiatrique, Amiens
- CS No. 61: CHU Pellegrin, Service Ophtalmologie, Bordeaux
- CS No. 86: Clinique Ophtalmologique, Centre Saint Victor, Centre Hospitalier Universitaire d'Amiens, Amiens

#### Germany

- CS No. 2: University Medical Center, Johannes Gutenberg University, Department of Ophthalmology, Mainz
- CS No. 5: Faculty of Medicine Mannheim of the Ruprecht-Karls-University Heidelberg, Department of Ophthalmology, Mannheim
- CS No. 9: University Hospital Tuebingen (UKT), STZ Biomed & STZ Eyetrial at the Center for Ophthalmology, Tuebingen
- CS No. 11: University Eye Hospital Munich, Munich
- CS No. 15: University of Bonn, Department of Ophthalmology, Bonn
- CS No. 21: University Medical Center Hamburg-Eppendorf, Department of Ophthalmology, Hamburg
- CS No. 24: University of Freiburg, Department of Ophthalmology, Freiburg
- CS No. 27: University Eye Hospital, Leipzig
- CS No. 43: RWTH Aachen University, Department of Ophthalmology, Aachen

Ophthalmologica 2014;231:180–184 DOI: 10.1159/000359987 nloaded by: J. Cunha-Vaz - 114768 55.146.122 - 4/7/2014 11:12:10 AM

- CS No. 44: University Eye Clinic, Center for Vision Science, Bochum
- CS No. 54: University of Düsseldorf, Department of Ophthalmology,
  Düsseldorf
- CS No. 55: Eye Centre Spreebogen, Berlin
- CS No. 56: University of Heidelberg, International Vision Correction Research Centre (IVCRC), Heidelberg
- CS No. 59: Johann Wolfgang Goethe-University Frankfurt, Department of Ophthalmology, Frankfurt
- CS No. 65: Justus-Liebig-University-Giessen, Department of Ophthalmology, Giessen
- CS No. 77: Universität zu Köln, Zentrum für Augenheilkunde, Köln

#### Greece

- CS No. 57: University of Crete, Institute of Vision and Optics (IVO), Crete
- CS No. 71: Laboratory of Research and Clinical Applications in Ophthalmology, Aristotle Univ. of Thessaloniki, A'Department of Ophthalmology, AHEPA Univ. Hospital, Thessaloniki

#### Ireland

CS No. 31: Mater Vision Institute (MVI), Dublin

#### Israel

CS No. 60: Tel Aviv Sourasky Medical Center, Department of Ophthalmology, Tel Aviv

#### Italy

- CS No. 16: University of Milan, Centre for Clinical Trials at San Paolo Hospital, Milan
- CS No. 20: G. B. Bietti Foundation IRCCS, Rome
- CS No. 34: Luigi Sacco Hospital, University of Milan, Department of Ophthalmology, Milan
- CS No. 36: Catholic University, Institute of Ophthalmology, Rome
- CS No. 37: Dipartimento di Scienze Biomediche, Biotecnologiche e Transazionali S.Bi.Bi.T., Parma
- CS No. 39: University of Padova, Department of Ophthalmology, Center for Clinical Trials, Padova
- CS No. 50: University of Udine, Department of Ophthalmology, Udine
- CS No. 63: University G. d'Annunzio of Chieti-Pescara, Excellence Eye Research Centre, Chieti
- CS No. 64: Ophthalmic Clinic of the University of Bari, Bari
- CS No. 67: University Vita Salute Scientific Institute of San Raffael, Department of Ophthalmology, Milan

## Poland

CS No. 33: Poznan University of Medical Sciences, Department of Ophthalmology, Poznan

### Portugal

- CS No. 1: AIBILI Association for Innov. and Biom. Research on Light and Image, Coimbra
- CS No. 28: Instituto de Oftalmologia Dr. Gama Pinto, Lisbon
- CS No. 32: Oporto Medical School Hospital S. João, Department of Ophthalmology, Oporto
- CS No. 62: Centro Hospitalar de Lisboa Central, Centro de Investigação, Serviço de Oftalmologia, Lisbon
- CS No. 70: University Hospital of Coimbra, Ophthalmology Department, Coimbra
- CS No. 80: Instituto de Retina e Diabetes Ocular de Lisboa (IRL), Lisbon
- CS No. 82: Espaço Médico de Coimbra, Coimbra

#### Slovakia

CS No. 87: Department of Ophthalmology, Comenius University, Bratislava, Slovakia

#### Slovenia

CS No. 23: University Medical Centre of Ljubljana, University Eye Hospital, Ljubljana

#### Spain

- ĆS No. 4: IOBA Instituto Universitario Oftalmobiologia Aplicada, Valladolid
- CS No. 7: Vissum Corporación Oftalmológica Alicante, Alicante
- CS No. 26: Centro de Oftalmología Barraquer, Barcelona
- CS No. 38: Institut Català de Retina (ICR), Clinical Trial Unit, Barcelona
- CS No. 41: Centro Médico Teknon, Institut de la Màcula i de la Retina, Barcelona
- CS No. 51: Fundación para la Investigacion Biomedica y Sanitaria (FISABIO), Oftalmología Médica, Valencia
- CS No. 52: Universitary Hospital Josep Trueta of Girona, Department of Ophthalmology, Girona
- CS No. 74: Hospital Vall d'Hebrón, Department of Ophthalmology, Barcelona
- CS No. 75: Vallés Oftalmologia Research, Barcelona
- CS No. 78: Instituto Oftalmologico Fernandez-Vega, Oviedo

#### Switzerland

- CS No. 22: Inselspital, University of Bern, Department of Ophthalmology, Bern
- CS No. 49: Jules Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne
- CS No. 85: Clinical Research Centre Mémorial A. de Rothschild, Geneva

#### The Netherlands

- CS No. 17: Department of Ophthalmology, Radboud University Medical Centre, Nijmegen
- CS No. 25: Academic Medical Center, Department of Ophthalmology, Amsterdam
- CS No. 40: Rotterdam Eye Hospital, Rotterdam
- CS No. 76: University Eye Clinic, Maastricht

#### United Kingdom

- CS No. 10: NIHR Moorfields Clinical Research Facility, Moorfields Eye Hospital, NHS Foundation Trust, London
- CS No. 35: The Queen's University and Royal Group of Hospitals Trust, Ophthalmology and Vision Science, Belfast
- CS No. 53: Gloucestershire Hospitals NHS Foundation Trust, Clinical Trials Unit, Department of Ophthalmology, Cheltenham
- CS No. 58: Royal Liverpool University Hospital, Clinical Eye Research Centre, St. Paul's Eye Unit, Liverpool
- CS No. 66: Frimley Park Hospital Foundation Trust, Ophthalmology Clinical Trials Unit, Frimley
- CS No. 68: Heart of England NHS Trust, Ophthalmic Research Unit, Birmingham
- CS No. 69: King's Health Partners, Laser and Retinal Research Unit, London
- CS No. 79: Clinical Trials Unit, Oxford Eye Hospital, Oxford
- CS No. 81: Royal Surrey County Hospital, NHS Foundation Trust, Ophthalmic Research Unit, Guildford
- CS No. 84: ICORG, Imperial College Ophthalmologic Research Group, London

Prepared by C. Martinho and D. Fernandes (EVICR.net).